Jiang Yu-Ting, Chen Kai-Hua, Liang Zhong-Guo, Yang Jie, Qu Song, Li Ling, Zhu Xiao-Dong
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi, People's Republic of China.
Key Laboratory of Early Prevention and Treatment for Regional High-Incidence- Tumor, Guangxi Medical University, Ministry of Education, Guangxi, People's Republic of China.
Cancer Manag Res. 2022 Aug 31;14:2583-2596. doi: 10.2147/CMAR.S377731. eCollection 2022.
We aimed to select optimal candidates benefiting from the addition of induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) in advanced N-stage nasopharyngeal carcinoma (NPC).
A total of 624 NPC patients with N2-3 stage received CCRT with or without IC were retrospectively reviewed. We constructed a nomogram for predicting overall survival (OS) based on the result of the multivariate analysis in the training cohort (n = 468) and then tested it on the validation cohort (n = 156). Harrell's concordance indices (C-index) and time-independent receiver operating characteristic (tdROC) analysis were applied to evaluate the discriminatory ability of the nomogram and compare it with TNM staging. IC plus CCRT was compared with CCRT in the whole cohort and two risk groups based on the nomogram with balanced baseline characteristics. In addition, acute toxicities were compared between different treatment groups.
The nomogram showed good prognostic accuracy with a C-index of 0.716 (95% CI 0.669-0.763) in the validation cohort. The 5-year OS of low and high-risk groups stratified by the nomogram were significantly different. IC+CCRT was significantly associated with superior OS as compared with CCRT (75.4 vs 52.6%, p = 0.009) in the high-risk group. However, no significant difference between IC plus CCRT and CCRT was observed (p = 0.843) in the low-risk group. IC plus CCRT was associated with more grade 1-4 acute toxicities.
Our study can help clinicians select NPC patients with advanced N stage who benefit from IC.
我们旨在筛选出在晚期N期鼻咽癌(NPC)中,从诱导化疗(IC)联合同步放化疗(CCRT)中获益的最佳候选患者。
回顾性分析了624例接受或未接受IC的N2-3期NPC患者。我们根据训练队列(n = 468)的多变量分析结果构建了一个预测总生存期(OS)的列线图,然后在验证队列(n = 156)中进行测试。应用Harrell一致性指数(C指数)和非时间依赖性受试者工作特征(tdROC)分析来评估列线图的鉴别能力,并将其与TNM分期进行比较。根据具有平衡基线特征的列线图,在整个队列和两个风险组中比较IC联合CCRT与CCRT。此外,还比较了不同治疗组之间的急性毒性。
验证队列中列线图显示出良好的预后准确性,C指数为0.716(95%CI 0.669-0.763)。根据列线图分层的低风险和高风险组的5年总生存期有显著差异。在高风险组中,与CCRT相比,IC+CCRT与更好的总生存期显著相关(75.4%对52.6%,p = 0.009)。然而,在低风险组中,未观察到IC联合CCRT与CCRT之间的显著差异(p = 0.843)。IC联合CCRT与更多的1-4级急性毒性相关。
我们的研究可以帮助临床医生筛选出从IC中获益的晚期N期NPC患者。